Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Cipla's new triple combination Antiretroviral Drug approved

Posted On: 2018-09-12 08:42:48

The South African Health Products Regulatory Authority (SAHPRA) has approved Cipla's latest first-line triple-combination antiretroviral (ARV) treatment for HIV. The new combination medicine commonly referred to as TLD, is a combination of tenofovir (TDF), lamivudine (3TC) and dolutegravir (DTG).

In future, TLD will be manufactured at Cipla's facilities in Durban and Uganda, reinforcing Cipla's commitment to produce medicines in Africa for Africa and ensuring more affordable treatment for patients.

Head of Manufacturing for Cipla South Africa, Ajay Kumar Pal, said the reason for the new formulation complexity related to the three different processes required for the three active pharmaceutical ingredients (APIs). In addition to the considerable technology and infrastructure investment of more than R48m (including a machine worth R16m), there are also additional complexities pertaining to the double coating and compression of the tablet, and the product also undergoes exhaustive testing at different stages of manufacturing.

Cipla's investment in infrastructure aligns with the government's request to support local industries to stimulate economic growth. Manufacturing and investment in infrastructure have been identified by the World Bank, and in the United Nations Sustainable Development Goals, as the multiplier for job creation, as well as economic growth and development in any country. Cipla continues to work closely with government in this regard and to ensure that people have access to affordable treatment.

Cipla has a legacy of pioneering affordable ARVs: in 2001, it produced the world-first three-in-one fixed combination drug, available at less than $1 per day, thereby enabling countless more patients to have access to life-saving medication. This new fixed-dose combination - an addition to Cipla's comprehensive portfolio of HIV medication - is recommended by the World Health Organisation (WHO) as a preferred first-line regimen.

Cipla South Africa CEO, Paul Miller, said: "We're always focused on ensuring that patients benefit by having access to quality, affordable ARVs. DTG is considered a best-in-class medicine providing many clinical benefits for people living with HIV. With DTG replacing efavirenz (EFV) in the first-line fixed dose combination treatment thereby reducing the likelihood of treatment failure, TLD has the potential to reduce overall treatment costs."

According to UNAIDS, "antiretroviral therapy using dolutegravir has several advantages over other regimens, including clinical superiority, improved side-effect profile, and reduced risk of viral resistance".

Shares of CIPLA LTD. was last trading in BSE at Rs.653.75 as compared to the previous close of Rs. 667.4. The total number of shares traded during the day was 171216 in over 3110 trades.

The stock hit an intraday high of Rs. 675 and intraday low of 652. The net turnover during the day was Rs. 114139196.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

BLS International Services Ltd introduces 'Premium Lounge' service in London

Kridhan Infra Limited's Singapore Subsidiary Swee Hong wins Orders worth INR 195 Crores

PSP Projects Ltd bags orders worth Rs. 372.47 crores

B.L. Kashyap & Sons standalone net profit rises in the Q2

Premier Explosives Ltd receives licenses to manufacture Propellants, HTPB and Ammonium Perchlorate

Everest Group Names HCL Technologies a Leader for IT Infrastructure Services Automation

Apollo Micro Systems Ltd enters into MOU with Israeli firm

CARE assigns ratings to Kamdhenu Limited

Surya Roshni Ltd bags order of Rs. 59 crore

RAJNISH WELLNESS LIMITED announces H1-FY19 Financial Results

MY FM Hikes Ad rates by 15%

TCS Teams up with SAP to Build the Intelligent Rail Digital Maintenance Solution, Powered by SAP® Leonardo

Vikas Ecotech updates on promoter share sale

PVR opens screen at Maruti Solaris Mall in Anand ,Gujrat

SPML Infra Ltd. wins Rs. 475 million arbitration award against Jharkhand Urja Utpadan Nigam Ltd.

Siemens Ltd Board Recommends Dividend of Rs. 7 for 2018

HDFC disburses over Rs 1,100 crs subsidy to 51,000 first time home buyers under PMAY Scheme

YES BANK'S Overall Long-term Rating of 'ICRA AA+' Retained by ICRA Ratings

Seamec Ltd announces contract for SEAMEC Princess for 7 days

Rajesh Exports Ltd announces Q2 FY19 results

Gravita India Limited revenue up by 30% to 292.72 crores in Q2 FY19

MRPL H1 FY'19: Net Profit INR 281 crore and GRM of 6.29 $/bbl against 6.30 $/bbl on HoH

Polyplex Corporation Ltd Board declares Interim Dividend of Rs. 10 for 2018-19

Astral Poly Technik Ltd Board declares Interim Dividend of Rs. 0.30 for 2018-19

Sandur Manganese & Iron Ores Ltd board declares interim dividend of Rs. 3.5 for 2018-19

Renascent Power Signs SPA to acquire 75.01% stake in Prayagraj Power Generation Company Limited

Siemens Ltd. announces Q4 FY 2018 results

G G Automotive Gears Ltd Q2 PAT higher at Rs. 1.04 crore

Dhabriya Polywood Ltd Q2 net profit drops to Rs. 1.43 crore

Rama Paper Mills Ltd Q2 net profit jumps to Rs. 2.72 crores

GPT Infraprojects Ltd Q2 consolidated net profit falls to Rs. 2.86 crore

Rajesh Exports Ltd Q2 net profit at Rs. 31.48 crores

Urbanknitt Fabs Ltd posts consolidated Q2 net profit of Rs. 0.15 crore

Gravita India Ltd Q2 FY19 consolidated PAT slides to Rs. 6.37 crores

RTS Power Corporation Ltd Q2 net profit higher at Rs. 1.29 crore

Sreeleathers Ltd Q2 net profit climbs to Rs. 13.67 crores

GSL Nova Petrochemicals Ltd Q2 net profit climbs to Rs. 3.62 crores

Vallabh Steels Ltd Q2 net profit up at Rs. 0.20 crore

Vedavaag Systems Ltd Q2 net profit at Rs. 2.47 crores

Reliance Infrastructure Ltd Q2 net profit at Rs. 277.19 crores

Mansi Finance Chennai Ltd Q2 PAT climbs to Rs. 3.28 crores

Rohit Ferro-Tech Ltd Q2 FY19 loss at Rs. 38.33 crores

Genesys International Corporation Ltd Q2 net profit declines to Rs. 2.35 crores

Kanishk Steel Industries Ltd up at Rs. 1.01 crore

Mount Shivalik Industries Ltd posts loss of Rs. 1.97 crore

Ruttonsha International Rectifier Ltd posts five-fold rise in net profit during Q2 FY19

Confidence Petroleum India Ltd Q2 consolidated PAT higher at Rs. 16.20 crores

NBCC India Ltd reports net profit of Rs. 72.76 crores in Q2 FY19

Freshtrop Fruits Ltd Q2 PAT at Rs. 1.25 crore

Chordia Food Products Ltd Q2 net profit drops to Rs. 0.72 crore







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2018